Integrated Diagnostics Holdings Plc Notice of Results
1 June 2022
(London) Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, will publish its results for the quarter ended 31 March 2022 on Wednesday, 8 June 2022 at 7am (UK).
An analyst and investor call will be hosted at 14pm (UK) | 15pm (Egypt) on Wednesday, 8 June 2022. You can access the call by clicking on this link, and you may dial in using the conference call details below:
• Event number: 2372 285 1168
• Event password: 7qdVVHnZT46
For more information about the event, please contact: halaa@EFG-HERMES.com
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned IDH a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 502 branches as at year-end 2021, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com.
The person responsible for arranging the release of this announcement is Nancy Fahmy, Investor Relations Director at IDH.
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | firstname.lastname@example.org